Tresiba all set for Japanese launch
Japanese authorities have approved the price of Novo Nordisks long-acting insulin Tresiba, which gives the Danish diabetes group a specific date for launch of the drug in Japan.
by Stefan Singh Kailay
Novo Nordisk may have been given the thumbs down in the US when the FDA rejected the Danish company’s application for marketing approval of the long-acting basal insulin, Tresiba, but the Japanese launch of the product is moving ahead as planned.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
